11/20
01:00 am
ipha
Innate Pharma Releases Its 2025 Financial Calendar
High
Report
Innate Pharma Releases Its 2025 Financial Calendar
11/19
01:05 am
ipha
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 [Yahoo! Finance]
Low
Report
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501 [Yahoo! Finance]
11/19
01:00 am
ipha
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
Low
Report
Innate Pharma Announces Publication in Science Immunology Highlighting Innovative Next-generation ANKET® IPH6501
11/13
03:35 am
ipha
Discover 3 Promising Penny Stocks With Over US$90M Market Cap [Yahoo! Finance]
Medium
Report
Discover 3 Promising Penny Stocks With Over US$90M Market Cap [Yahoo! Finance]
11/13
01:00 am
ipha
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
Medium
Report
Innate Pharma Reports Third Quarter 2024 Business Update and Financial Results
11/12
08:33 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
11/8
01:00 am
ipha
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
Low
Report
Innate Pharma Highlights Data From Its Innovative Oncology Portfolio Selected for the SITC Annual Meeting 2024
11/7
01:00 am
ipha
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
Medium
Report
Innate Pharma Announces Conference Call and Webcast for Third Quarter 2024 Results and Business Updates
10/29
02:00 am
ipha
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
Medium
Report
Innate Pharma Announces Its Participation in Upcoming Investor Conferences
10/14
01:00 am
ipha
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
Low
Report
Innate Pharma Appoints Jonathan Dickinson as New Chief Executive Officer and Chairman of the Executive Board
9/30
01:13 am
ipha
Fed's Powell set to speak as economists fret about a policy mistake, election risk [Yahoo! Finance Canada]
Medium
Report
Fed's Powell set to speak as economists fret about a policy mistake, election risk [Yahoo! Finance Canada]
9/30
01:07 am
ipha
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 [Yahoo! Finance]
Medium
Report
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024 [Yahoo! Finance]
9/30
01:00 am
ipha
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
Medium
Report
Innate Pharma to Host KOL Scientific Symposium on Immunotherapy in New York on October 3, 2024
9/23
07:24 am
ipha
FDA grants IND clearance for Innate Pharma's solid tumour trial [Yahoo! Finance]
Low
Report
FDA grants IND clearance for Innate Pharma's solid tumour trial [Yahoo! Finance]
9/23
01:05 am
ipha
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors [Yahoo! Finance]
Low
Report
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors [Yahoo! Finance]
9/23
01:00 am
ipha
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
Low
Report
Innate Pharma Announces FDA Clearance of the IND for IPH4502, a Nectin-4 ADC to Be Developed in Solid Tumors
9/18
07:30 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
Low
Report
Innate Pharma S.A. (NASDAQ: IPHA) was upgraded by analysts at Evercore ISI to a "strong-buy" rating.
9/13
08:02 am
ipha
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
Neutral
Report
Innate Pharma S.A. (NASDAQ: IPHA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $11.50 price target on the stock.
9/12
01:00 am
ipha
Innate Pharma Reports First Half 2024 Business Update and Financial Results
Medium
Report
Innate Pharma Reports First Half 2024 Business Update and Financial Results
9/9
01:00 am
ipha
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
Low
Report
Innate Pharma SA: Monalizumab Data From NeoCOAST-2 Phase 2 Study in Early-Stage NSCLC Presented at the WCLC 2024
9/5
01:00 am
ipha
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
High
Report
Innate Pharma Announces Conference Call and Webcast for First Half 2024 Financial Results and Business Update
9/4
01:00 am
ipha
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference
Low
Report
Innate Pharma Announces Its Participation in the H.C. Wainwright 26th Annual Global Investment Conference